Dibenzazepine Market
Number of pages: 100 | Report Format: PDF | Published date: June 13, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
CAGR |
3.6% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug, Indication, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global dibenzazepine market is expected to register a revenue CAGR of 3.6% during the forecast period.
Dibenzazepine Market Fundamentals
Dibenzazepine is a chemical molecule that describes a group of tricyclic compounds having a dibenzazepine core structure. It has been widely employed in medicinal chemistry as a scaffold for synthesizing several medicines with various uses. Numerous dibenzazepine derivatives have been created and are now being used as antidepressants. The tricyclic antidepressant (TCA) drug imipramine is a well-known example. Imipramine and other TCAs reduce the symptoms of depression by raising the levels of certain neurotransmitters in the brain, such as serotonin and norepinephrine. Additionally, antipsychotic drugs have also been developed with derivatives of dibenzazepines. For instance, the antipsychotic drug loxapine, a dibenzazepine molecule, is used to treat diseases like schizophrenia. By blocking certain brain receptors, loxapine suppresses the symptoms of psychosis.
All three members of the dibenzazepine family of antiepileptic medications—carbamazepine (CBZ), oxcarbazepine (OXC), and eslicarbazepine acetate (ESL)—are assumed to function largely as sodium channel blockers (SCBs). The structural differences between ESL and CBZ, and OXC, however, lead to variations in pharmacokinetics, pharmacodynamics, and metabolism. Since introducing phenytoin as an antiepileptic medication (AED), sodium channel blockers (SCBs) have been a key component of the pharmacological therapy of focal and generalized tonic-clonic seizures.
Dibenzazepine Market Dynamics
The rise in epilepsy, and bipolar disorder, government initiatives to raise public awareness, technological advancements, and the increasing introduction of dibenzazepine medications for the treatment of epilepsy by market players at competitive prices are the main drivers of the dibenzazepine market's expansion. According to a piece titled "What is the worldwide prevalence of bipolar disorder?" that was published in October 2021, bipolar disorder has a 0.5% lifetime prevalence and a 1% lifetime prevalence worldwide. Compared to bipolar II disorder, bipolar I disorder is more prevalent. 1 in every 8 individuals worldwide suffers from a mental condition, according to the World Health Organization's (WHO) major statistics revised in June 2022. The COVID-19 epidemic has increased the number of persons infected who suffer from anxiety and depressive illnesses greatly increased in 2020. The same source estimates that 40 million individuals will have bipolar diseases in 2020. Depressive episodes and times of manic symptoms alternate for people with bipolar disease. Medical issues are particularly prevalent among Chinese bipolar disorder (BD) patients, according to a March 2022 paper titled "The prevalence and clinical correlates of medical disorders comorbidities in patients with bipolar disorder." Patients with BD who smoke, have frequent depressive episodes, are more likely to have coexisting medical conditions, and are sicker for longer.
Another major driver of the dibenzazepine drug industry's expansion globally is the increase in mental health issues since many consumers depend on these drugs to treat depression, anxiety disorders, and other mental illnesses. Drugs that treat depression, OCD, childhood enuresis, major depressive disorder, severe anxiety disorder, bipolar disorder, post-traumatic stress disorder (PTSD), and social anxiety disorder are all examples of disorders that can be treated with dibenzazepine drugs. The prevalence of depression ranges from 2% to 6% worldwide, and older people are more likely than younger people to have depression. WHO estimates that 264 million people worldwide, of all ages will be suffering from depression in 2020. As a result, the market for dibenzazepine drugs is anticipated to expand due to the increased incidence of mental health conditions.
However, the development of the global pharmaceutical industry might be hampered by issues, including the high cost of patented medications, the lengthy approval procedure, and the limited access to these medications in emerging and underdeveloped countries worldwide.
Dibenzazepine Market Ecosystem
The global dibenzazepine market is analyzed from the following perspectives by drug, indication, distribution channel, and region.
Dibenzazepine Market by Drug
Based on the drug, the global dibenzazepine market is segmented into carbamazepine, oxcarbazepine, eslicarbazepine, rufinamide, and others.
The carbamazepine segment is likely to show significant growth during the forecast period. It has anticonvulsant properties. It functions by reducing the nerve impulses that lead to pain and seizures, such as those brought on by trigeminal neuralgia and diabetic neuropathy. Additionally also used to treat bipolar disorder. Patients with bipolar I disorder (manic-depressive disorder, a condition that causes episodes of depression, episodes of mania, and other abnormal moods) can also benefit from the use of carbamazepine extended-release capsules (Equetro brand only) to treat episodes of mania (frenzied, abnormally excited or irritable mood) or mixed episodes (symptoms of mania and depression that occur simultaneously). For instance, the important factors driving the segment expansion include the rising prevalence of depression worldwide, increased awareness of the condition, and the introduction of innovative biologics. The major causes of depression are social isolation and stressful work environments, both of which are associated with an increase in the prevalence of depression. According to World Health Organization (WHO) data updated in September 2021, depression is a common mental condition that affects an estimated 5.0% of individuals globally.
Dibenzazepine Market by Indication
Based on the indication, the global dibenzazepine market is segmented into bipolar disorder, epilepsy, seizures, and others.
The epilepsy segment will likely grow at a significant revenue CARG of 2.4% during the forecasted period. Increased awareness of the illness and the growing prevalence of epilepsy worldwide are significant factors driving the segment’s development. Epilepsy affects over 50 million individuals globally, making it one of the most prevalent neurological conditions worldwide. Epilepsy affects an estimated 5 million individuals worldwide annually. Epilepsy is thought to be diagnosed in 49 out of every 100,000 persons annually in high-income nations. This number can reach 139 per 100 000 in low- and middle-income countries.
Dibenzazepine Market by Distribution Channel
Based on the distribution channel, the global dibenzazepine market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Hospital pharmacies are likely to dominate the market during the forecast period due to increased government investment in hospital treatment facilities in various countries and increased patient traffic. Hospital pharmacists are a valuable resource of pharmacological information and advice for medical professionals regarding dibenzazepine drugs. They include current details on dosage, medication interactions, side effects, and treatment recommendations. To optimize medicine therapy, encourage drug usage, and provide suggestions based on the patient's individual requirements, pharmacists work with healthcare teams.
Dibenzazepine Market by Region
Based on the region, the global dibenzazepine market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America showed significant growth in the market during the forecast period. The key cause driving the expansion of dibenzazepine medications is the rise in major depressive disorder instances across the globe. For instance, 5.7% of people over 60 years old and around 280.0 million people worldwide suffer from depression, according to data published by the WHO in September 2021. The National Institute of Mental Health reported in January 2022 that an estimated 21.0 million individuals in the US had at least one major depressive episode. In 2020, that figure accounted for 8.4% of all US adults. Other major drivers are rising bipolar disorder incidence and improved healthcare infrastructure. According to data from the National Alliance on Mental Illness, around 1 in 5 individuals in the United States experience mental illness in a given year. Severe maniacal and depressive episodes necessitate hospitalization to prevent people from hurting themselves or others. According to the NIMH, manic episodes that are so severe that a person needs emergency medical treatment are one of the characteristics of bipolar I disorder. Due to the urgent need to address this growing issue, the market for dibenzazepine medications is anticipated to expand. Additionally, a number of groups are promoting epilepsy awareness in the US. For instance, Purple Day, also known as Epilepsy Awareness Day, is observed yearly on March 26 in an effort to reduce stigma and raise public knowledge of this brain illness.
The market for dibenzazepine pharmaceuticals in Europe accounted for a sizable revenue share in 2022, driven by rising public awareness of treatments for mental illnesses. Along with illness prevalence, factors including increasing disposable income, high healthcare spending, the development of infrastructure, and the availability of qualified personnel to deal with the patient pool would encourage more people to seek treatment. Additionally, product introductions by regional market players to address issues with various anxiety disorders increase the availability of medications. Additionally, a healthy pipeline that leads to new product launches in the future will promote revenue development in the region.
Due to the high incidence of mental diseases in the region, Asia Pacific is predicted to see a larger CAGR over the course of the projection period than other regions. India and China are among the nations with the highest rates of mental illnesses, including anxiety, schizophrenia, and bipolar disorder, according to WHO data. Along with government initiatives, the market in this area is projected to be driven by APEC's Healthy Asia Pacific 2020 program launched in 2014.
Dibenzazepine Market Competitive Landscape
Some of the prominent market players in the global dibenzazepine market include,
Dibenzazepine Market Strategic Development
Dibenzazepine is a chemical molecule that describes a group of tricyclic compounds having a dibenzazepine core structure. It has been widely used in medicinal chemistry as a scaffold for the synthesis of several medicines with a variety of uses
The North America region dominated the global dibenzazepine market in 2022.
The revenue CAGR of the dibenzazepine market during the forecast period will be 3.6%.
Some of the prominent market players in the global dibenzazepine market include Novartis Corporation, Sunovion Pharmaceuticals, Inc., and Teva Pharmaceuticals, Inc.
The hospital pharmacies segment led the global dibenzazepine market in 2022.
*Insights on financial performance are subject to the availability of information in the public domain